Notice Number: NOT-DA-19-057

Key Dates
Release Date: August 8, 2019

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

This Notice is to inform potential applicants that the NIDA is revising the award budget language in RFA-DA-19-019 "HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)."

Part 2. Full Text of Announcement

Section II. Award Information

Award Budget

Currently reads:

“According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.”

Revised to read:

“Total funding support (direct costs, indirect costs, fee) normally may not exceed $252,131 for Phase I awards and $1,680,879 for Phase II awards. NIH has received a waiver from SBA, as authorized by statute, to exceed these total award amount hard caps for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. “

This updated language corresponds to the current SBIR Omnibus Solicitations (PA-19-272 and PA-19-273). For future receipt dates of this RFA, please follow the budget limitations as stated in the Omnibus Solicitation in affect at the time of your submission. You can find the current SBIR Omnibus Solicitations at https://sbir.nih.gov/funding.

Inquiries

Please direct all inquiries to:

Elena Koustova, PhD, MBA
National Institute on Drug Abuse (NIDA)
Telephone:301-496-8768
Email: [email protected]